Wockhardt USA and Wockhardt Americas, having headquartered at Warwick, are wholly owned subsidiaries of Wockhardt Limited. The parent company is headquartered in Mumbai, India.
Wockhardt is a global research driven health care company devoted to discovery, development, manufacturing and marketing of pharmaceuticals, nutritional and other medical products.
Wockhardt is also actively engaged in providing specialty healthcare services through its chain of state of the art equipped super specialty hospitals situated at several locations. Currently, Wockhardt has active presence in more than 20 countries.
In its continued commitment to serve its US customers efficiently, Wockhardt established Wockhardt subsidiary Wockhardt Americas in 1998 and Wockhardt USA in 2005. The key objective of Wockhardt subsidiaries is to provide quality drugs at affordable prices to the US customers. Currently, Wockhardt has six approved products - Famotidine, Ranitidine, Captopril, Enalapril, Bethanechol Chloride, and Cefuroxime Axetil.
In addition Wockhardt has over 15 applications under these FDA review and 60 projects in various stages of the developmental pipeline and they would be available to the US customers in future. Currently, more than 150 R & D scientists at various levels at Wockhardt in India are supporting the company’s US generics business.
Wockhardt Limited
Wockhardt Ltd. is a flagship company of the Wockhardt Group and is a global, pharmaceutical and biotechnology company that has grown by leveraging two powerful trends impacting the world of medicine - globalization and biotechnology. The Company has a market capitalization of US$ 1.3 billion and an annual turnover of US$ 285 million (Rs. 12.39 billion).
Wockhardt today, is distinguished by a strong and growing presence in the world’s leading markets, with half of its revenue coming from Europe and the United States.
Wockhardt acquired UK based CP Pharmaceuticals Limited to fuel its European growth and became one of the top 10 generic pharmaceutical companies in the UK.
CP Pharmaceuticals has four key business over consisting of a branded portfolio of hospital drugs, generics, contract manufacturing and exports. It has 225 product licenses, providing the company with a significant growth potential and has spent over seven million sterling pounds on acquiring brands in recent years.
Wockhardt acquired Esparma GmbH in 2004 to further strengthen its presence in the German and European market.
Esparma has a sizeable portfolio of over 135 marketing authorizations, of which 67 are in Germany. The company also has 9 international patents and 94 trademarks.
